FY2024 EPS Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Boosted by Leerink Partnrs

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Research analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for Fulcrum Therapeutics in a report released on Thursday, September 12th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($0.32) per share for the year, up from their previous forecast of ($0.43). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Fulcrum Therapeutics’ Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($1.06) EPS.

A number of other brokerages have also recently weighed in on FULC. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $10.00 to $2.00 in a research report on Thursday, September 12th. Cantor Fitzgerald cut Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. Royal Bank of Canada cut Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $15.00 to $4.00 in a research report on Thursday, September 12th. Stifel Nicolaus cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $22.00 to $3.00 in a research report on Thursday, September 12th. Finally, Leerink Partners reiterated a “market perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Fulcrum Therapeutics has an average rating of “Hold” and an average target price of $9.33.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC opened at $3.18 on Monday. The stock’s 50 day moving average price is $8.35 and its two-hundred day moving average price is $8.21. Fulcrum Therapeutics has a 52-week low of $2.87 and a 52-week high of $13.70. The stock has a market capitalization of $197.65 million, a P/E ratio of -1.99 and a beta of 2.23.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.93. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. The firm had revenue of $80.00 million for the quarter, compared to analysts’ expectations of $80.00 million. During the same quarter in the prior year, the firm posted ($0.38) earnings per share.

Hedge Funds Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vestal Point Capital LP bought a new position in Fulcrum Therapeutics in the 4th quarter worth approximately $6,919,000. Opaleye Management Inc. bought a new position in Fulcrum Therapeutics during the 4th quarter valued at $878,000. ADAR1 Capital Management LLC bought a new position in Fulcrum Therapeutics during the 4th quarter valued at $4,302,000. Jane Street Group LLC boosted its stake in Fulcrum Therapeutics by 54.3% during the 1st quarter. Jane Street Group LLC now owns 535,062 shares of the company’s stock valued at $5,051,000 after purchasing an additional 188,212 shares in the last quarter. Finally, Mass General Brigham Inc bought a new position in Fulcrum Therapeutics during the 1st quarter valued at $1,939,000. 89.83% of the stock is owned by institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.